These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 22095371)

  • 1. Frequency of HER2 heterogeneity by fluorescence in situ hybridization according to CAP expert panel recommendations: time for a new look at how to report heterogeneity.
    Allison KH; Dintzis SM; Schmidt RA
    Am J Clin Pathol; 2011 Dec; 136(6):864-71. PubMed ID: 22095371
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genotypic intratumoral heterogeneity in breast carcinoma with HER2/neu amplification: evaluation according to ASCO/CAP criteria.
    Brunelli M; Manfrin E; Martignoni G; Miller K; Remo A; Reghellin D; Bersani S; Gobbo S; Eccher A; Chilosi M; Bonetti F
    Am J Clin Pathol; 2009 May; 131(5):678-82. PubMed ID: 19369627
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic heterogeneity in HER2 testing may influence therapy eligibility.
    Bernasconi B; Chiaravalli AM; Finzi G; Milani K; Tibiletti MG
    Breast Cancer Res Treat; 2012 May; 133(1):161-8. PubMed ID: 21901388
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of American Society of Clinical Oncology/College of American Pathologists guideline recommendations on HER2 interpretation in breast cancer.
    Shah SS; Ketterling RP; Goetz MP; Ingle JN; Reynolds CA; Perez EA; Chen B
    Hum Pathol; 2010 Jan; 41(1):103-6. PubMed ID: 19762065
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The equivocally amplified HER2 FISH result on breast core biopsy: indications for further sampling do affect patient management.
    Striebel JM; Bhargava R; Horbinski C; Surti U; Dabbs DJ
    Am J Clin Pathol; 2008 Mar; 129(3):383-90. PubMed ID: 18285260
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fluorescence in situ hybridization (FISH) as primary methodology for the assessment of HER2 Status in adenocarcinoma of the breast: a single institution experience.
    Tubbs RR; Hicks DG; Cook J; Downs-Kelly E; Pettay J; Hartke MB; Hood L; Neelon R; Myles J; Budd GT; Moore HC; Andresen S; Crowe JP
    Diagn Mol Pathol; 2007 Dec; 16(4):207-10. PubMed ID: 18043283
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Silver in situ hybridization (SISH) for determination of HER2 gene status in breast carcinoma: comparison with FISH and assessment of interobserver reproducibility.
    Papouchado BG; Myles J; Lloyd RV; Stoler M; Oliveira AM; Downs-Kelly E; Morey A; Bilous M; Nagle R; Prescott N; Wang L; Dragovich L; McElhinny A; Garcia CF; Ranger-Moore J; Free H; Powell W; Loftus M; Pettay J; Gaire F; Roberts C; Dietel M; Roche P; Grogan T; Tubbs R
    Am J Surg Pathol; 2010 Jun; 34(6):767-76. PubMed ID: 20421783
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Determining true HER2 gene status in breast cancers with polysomy by using alternative chromosome 17 reference genes: implications for anti-HER2 targeted therapy.
    Tse CH; Hwang HC; Goldstein LC; Kandalaft PL; Wiley JC; Kussick SJ; Gown AM
    J Clin Oncol; 2011 Nov; 29(31):4168-74. PubMed ID: 21947821
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bright-field in situ hybridization for HER2 gene amplification in breast cancer using tissue microarrays: correlation between chromogenic (CISH) and automated silver-enhanced (SISH) methods with patient outcome.
    Francis GD; Jones MA; Beadle GF; Stein SR
    Diagn Mol Pathol; 2009 Jun; 18(2):88-95. PubMed ID: 19430296
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chromogenic in situ hybridization is a reliable method for detecting HER2 gene status in breast cancer: a multicenter study using conventional scoring criteria and the new ASCO/CAP recommendations.
    Gong Y; Sweet W; Duh YJ; Greenfield L; Fang Y; Zhao J; Tarco E; Symmans WF; Isola J; Sneige N
    Am J Clin Pathol; 2009 Apr; 131(4):490-7. PubMed ID: 19289584
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intratumoral heterogeneity of HER2/neu in breast cancer--a rare event.
    Hanna W; Nofech-Mozes S; Kahn HJ
    Breast J; 2007; 13(2):122-9. PubMed ID: 17319852
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HER2 assessment by immunohistochemical analysis and fluorescence in situ hybridization: comparison of HercepTest and PathVysion commercial assays.
    McCormick SR; Lillemoe TJ; Beneke J; Schrauth J; Reinartz J
    Am J Clin Pathol; 2002 Jun; 117(6):935-43. PubMed ID: 12047146
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Observer prediction of HER2 amplification in HercepTest 2+ breast cancers as a potential audit instrument.
    Going JJ
    Histopathology; 2011 Aug; 59(2):333-5. PubMed ID: 21884213
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Breast carcinomas with borderline (2+) HER2 immunohistochemistry: percentage of cells with complete membrane staining for HER2 and the frequency of HER2 amplification.
    Lee AH; Key HP; Bell JA; Hodi Z; Ellis IO
    J Clin Pathol; 2011 Jun; 64(6):490-2. PubMed ID: 21415056
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Determination of Her-2/Neu status in breast carcinoma: comparative analysis of immunohistochemistry and fluorescent in situ hybridization.
    Jimenez RE; Wallis T; Tabasczka P; Visscher DW
    Mod Pathol; 2000 Jan; 13(1):37-45. PubMed ID: 10658908
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of HER2 gene amplification in invasive breast cancer using a dual-color chromogenic in situ hybridization (dual CISH).
    Kato N; Itoh H; Serizawa A; Hatanaka Y; Umemura S; Osamura RY
    Pathol Int; 2010 Jul; 60(7):510-5. PubMed ID: 20594272
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RAI1 Alternate Probe Identifies Additional Breast Cancer Cases as Amplified Following Equivocal HER2 Fluorescence In Situ Hybridization Testing: Experience From a National Reference Laboratory.
    Hui L; Geiersbach KB; Downs-Kelly E; Gulbahce HE
    Arch Pathol Lab Med; 2017 Feb; 141(2):274-278. PubMed ID: 27959582
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Determination of HER2 amplification by in situ hybridization: when should chromosome 17 also be determined?
    Bartlett JM; Campbell FM; Mallon EA
    Am J Clin Pathol; 2008 Dec; 130(6):920-6. PubMed ID: 19019769
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New cutpoints to identify increased HER2 copy number: analysis of a large, population-based cohort with long-term follow-up.
    Jensen KC; Turbin DA; Leung S; Miller MA; Johnson K; Norris B; Hastie T; McKinney S; Nielsen TO; Huntsman DG; Gilks CB; West RB
    Breast Cancer Res Treat; 2008 Dec; 112(3):453-9. PubMed ID: 18193353
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of the 2013 American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 (HER2) testing of invasive breast carcinoma: a focus on tumours assessed as 'equivocal' for HER2 gene amplification by fluorescence in-situ hybridization.
    Bethune GC; Veldhuijzen van Zanten D; MacIntosh RF; Rayson D; Younis T; Thompson K; Barnes PJ
    Histopathology; 2015 Dec; 67(6):880-7. PubMed ID: 25913507
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.